can you use semaglutide while pregnant Ozempic and Wegovy's side effects and pregnancy risks need more attention Semaglutide, Fertility & Pregnancy |

Lancet 5-12-1979;1(8124):1041-1042

Key findings: CagriSema achieved up to 23% weight loss at 84 weeks Tirzepatide showed numerical superiority (~25.5%) The trial did not meet non-inferiority vs tirzepatide Clinical interpretation: Despite not meeting the primary endpoint, an important signal emerges: targeting multiple biological pathways remains a compelling strategy Why this matters: Reinforces obesity as a complex neuroendocrine disease Supports the concept that multi-hormonal approaches may better impact the defended weight set point Moves the field closer to precision, mechanism-based therapies Safety: Consistent with the GLP-1 class Mainly gastrointestinal adverse events, generally mild to moderate and transient Whats next: Ongoing development with higher-dose CagriSema Expansion of the REDEFINE program FDA decision expected by late 2026 Take-home message: The future of obesity treatment lies not in a single pathway, but in strategically combining mechanisms to sustainably shift weight biology

BPC-157s origin in gastric juice explains its profound impact on digestive health

Similarly, the Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity (SELECT) trial demonstrated a significant reduction in cardiovascular events in individuals with overweight or obesity, with subsequent analysis addressing prespecified kidney endpoints

Semaglutide, conversely, provides practical therapeutic administration through once-weekly injection or once-daily oral tablet